Zenas BioPharma, Inc. Statistics
Want to see ZBIO full AI Analyst Report?
Zenas BioPharma, Inc. (ZBIO) Stock Statistics & Valuation Metrics
Total Valuation
Zenas BioPharma, Inc. has a market cap or net worth of $1.92B. The enterprise value is $1.60B.
- Market Cap
- $1.92B
- Enterprise Value
- $1.60B
Share Statistics
Zenas BioPharma, Inc. has 67,817,795 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 67,817,795
- Owned by Insiders
- 16.00%
- Owned by Institutions
- 38.15%
Financial Efficiency
Zenas BioPharma, Inc.’s return on equity (ROE) is -1.56 and return on invested capital (ROIC) is -65.61%.
- Return on Equity (ROE)
- -1.56
- Return on Assets (ROA)
- -0.98
- Return on Invested Capital (ROIC)
- -65.61%
- Return on Capital Employed (ROCE)
- -0.66
- Revenue Per Employee
- 59.88K
- Profits Per Employee
- -2.26M
- Employee Count
- 167
- Asset Turnover
- 0.03
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Zenas BioPharma, Inc. is -2.84. Zenas BioPharma, Inc.’s PEG ratio is 0.03.
- PE Ratio
- -2.84
- PS Ratio
- 169.28
- PB Ratio
- 8.90
- Price to FCF
- -7.67
- Price to Operating Cash Flow
- -7.78
- PEG Ratio
- 0.03
Income Statement
In the last 12 months, Zenas BioPharma, Inc. had revenue of 10.00M and earned -377.74M in profits. Earnings per share was -8.44.
- Revenue
- 10.00M
- Gross Profit
- 10.00M
- Operating Income
- -211.38M
- Pretax Income
- -377.82M
- Net Income
- -377.74M
- EBITDA
- -370.43M
- Earnings Per Share (EPS)
- -8.44
Cash Flow
In the last 12 months, operating cash flow was -242.83M and capital expenditures -3,000, giving a free cash flow of -242.83M billion.
- Operating Cash Flow
- -242.83M
- Free Cash Flow
- -242.83M
- Free Cash Flow per Share
- -3.67
Dividends & Yields
Zenas BioPharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -13.04%
- Earnings Yield
- -28.67%
Stock Price Statistics
- Beta
- 0.38
- 52-Week Price Change
- -12.94%
- 50-Day Moving Average
- 29.02
- 200-Day Moving Average
- 25.28
- Relative Strength Index (RSI)
- 51.60
- Average Volume (3m)
- 667.46K
Important Dates
Zenas BioPharma, Inc. upcoming earnings date is Mar 22, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 22, 2027
- Ex-Dividend Date
- ―
Financial Position
Zenas BioPharma, Inc. as a current ratio of 5.61, with Debt / Equity ratio of 33.02%
- Current Ratio
- 5.61
- Quick Ratio
- 5.61
- Debt to Market Cap
- 0.05
- Net Debt to EBITDA
- 0.08
- Interest Coverage Ratio
- -28.85
Taxes
In the past 12 months, Zenas BioPharma, Inc. has paid -79.00K in taxes.
- Income Tax
- -79.00K
- Effective Tax Rate
- 0.00
Enterprise Valuation
Zenas BioPharma, Inc. EV to EBITDA ratio is -3.79, with an EV/FCF ratio of -7.86.
- EV to Sales
- 173.55
- EV to EBITDA
- -3.79
- EV to Free Cash Flow
- -7.86
- EV to Operating Cash Flow
- -7.86
Balance Sheet
Zenas BioPharma, Inc. has $585.31M in cash and marketable securities with $224.78M in debt, giving a net cash position of $360.54M billion.
- Cash & Marketable Securities
- $585.31M
- Total Debt
- $224.78M
- Net Cash
- $360.54M
- Net Cash Per Share
- $5.32
- Tangible Book Value Per Share
- $3.21
Margins
Gross margin is -656.60%, with operating margin of -4785.47%, and net profit margin of -4925.53%.
- Gross Margin
- -656.60%
- Operating Margin
- -4785.47%
- Pretax Margin
- -4923.08%
- Net Profit Margin
- -4925.53%
- EBITDA Margin
- -4576.75%
- EBIT Margin
- -4576.96%
Analyst Forecast
The average price target for Zenas BioPharma, Inc. is $44.80, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $44.80
- Price Target Upside
- 58.53% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- -26.67%
- EPS Growth Forecast
- -121.60%
Scores
- Smart Score
- 7
- AI Score
- 49
